Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alpha Cognition Inc. - Common Stock (NQ:ACOG)

8.630 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alpha Cognition Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Alpha Cognition (ACOG) Q2 2026 Earnings Call Transcript ↗
ZUNVEYL revenue surged 71% sequentially as repeat prescriber rates hit 76%. 
Via The Motley Fool
Topics Earnings
News headline image
Alpha Cognition Q2 Earnings Call Highlights ↗
Alpha Cognition (NASDAQ:ACOG) reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer’s treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the... 
Via MarketBeat
Topics Earnings
News headline image
Alpha Cognition Q2 2026 Earnings Call Transcript ↗
Alpha Cognition (NASDAQ:ACOG) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by... 
Via Benzinga
Topics Earnings
News headline image
Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition (NASDAQ:ACOG) Q1 Revenue Meets Estimates as Commercial Momentum Builds ↗
Via Chartmill
Alpha Cognition Inc. (NASDAQ:ACOG) Reports Q4 Revenue Miss Amid Strong Alzheimer's Drug Launch ↗
Via Chartmill
News headline image
Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease
From Alpha Cognition, Inc.
Via Business Wire
News headline image
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Q1 Earnings Call Highlights ↗
Alpha Cognition (NASDAQ:ACOG) reported 40% sequential revenue growth in the first quarter of 2026, as executives said commercial adoption of its Alzheimer’s treatment ZUNVEYL continued to build across... 
Via MarketBeat
Topics Earnings
News headline image
Alpha Cognition (ACOG) Q1 2026 Earnings Transcript ↗
Alpha Cognition (ACOG) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
From Alpha Cognition, Inc.
Via Business Wire
News headline image
Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
News headline image
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425
Dallas, Texas--(Newsfile Corp. - April 1, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on... 
Via Newsfile
News headline image
Alpha Cognition (ACOG) Q4 2025 Earnings Transcript ↗
Alpha Cognition (ACOG) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
From Alpha Cognition Inc.
Via Business Wire
News headline image
Water Giant With $7 Billion in Revenue Draws $7.5 Million Investment, and Shares Are Surging This Year ↗
This water solutions provider serves both consumers and businesses through recurring sales and a broad portfolio of regional brands. 
Via The Motley Fool
News headline image
Payments Stock Down 30% Draws $6 Million Bet as Company Posts $4 Billion in Revenue ↗
Euronet Worldwide runs a global payments platform, providing transaction processing and money transfer solutions across diverse markets. 
Via The Motley Fool
News headline image
Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences
From Alpha Cognition Inc.
Via Business Wire
News headline image
Solas Capital Loads Up On Kyndryl With 407,000 Shares Bought ↗
This technology firm delivers IT infrastructure and managed solutions to major enterprises across multiple global industries. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens
From Alpha Cognition Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.